Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory disorder22.02.07.0020.002780%Not Available
Respiratory distress22.02.01.0120.005560%Not Available
Restlessness19.11.02.002; 17.02.05.0210.007505%
Rhabdomyolysis15.05.05.0020.044476%
Seizure17.12.03.0010.042252%
Sensory disturbance17.02.07.006--Not Available
Sensory loss17.02.07.0070.002780%Not Available
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.004170%Not Available
Shock24.06.02.0020.011119%Not Available
Sideroblastic anaemia01.03.02.009--Not Available
Sinus tachycardia02.03.03.0100.004170%
Skin discolouration23.03.03.0050.002780%Not Available
Skin disorder23.03.03.0070.006949%Not Available
Skin exfoliation23.03.07.0030.006949%Not Available
Skin hyperpigmentation23.05.01.0030.002780%
Skin lesion23.03.03.0100.004170%Not Available
Somnolence19.02.05.003; 17.02.04.0060.013899%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.006115%Not Available
Splenomegaly01.09.02.001--Not Available
Status epilepticus17.12.03.0050.023628%Not Available
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.0050.029187%
Stillbirth18.01.02.002; 08.04.01.0060.005560%Not Available
Stupor17.02.04.007; 19.02.05.0040.002780%Not Available
Suicide attempt19.12.01.0040.038917%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.006949%
Systemic lupus erythematosus15.06.02.003; 10.04.03.004; 23.03.02.0060.002780%Not Available
Tachycardia02.03.02.0070.012509%Not Available
Therapeutic response increased08.06.01.021--Not Available
Thrombocytopenia01.08.01.0020.016679%Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.0030.002780%Not Available
The 8th Page    First    Pre   8 9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene